HCWB

HCW Biologics Inc.

Company with tickers: HCWB

CIK

1828673

CUSIP

40423R204

Shares Outstanding

6,734,104

Website

https://www.hcwbiologics.com/

Press releases and events scraped from the company's investor relations website. News and event listings link back to the original source.

Date	Event	Type
2026-04-20	Development of HCW11-018b (T Cell Engager), An Innovative Approach to Improve Bispecific T-Cell Engagers for Solid Tumor Therapy (Poster presented at AACR Annual Meeting 2026)	Shareholder meeting
2025-11-07	A Debut of HCWB’s 2nd Gen T-cell Engager IND-Enabling Study Data - 40th SITC2025 Poster	Event
2025-10-22	Video: Dr. Peter Rhode Participated in a Virtual Investor “What This Means” Segment About HCWB’s Second Generation Proprietary Immune Checkpoint Inhibitor	Event
2025-09-30	Video: Dr. Peter Rhode Participated in a Virtual Investor “What This Means” Segment About HCWB’s Second Generation Proprietary T-Cell Engager Program	Event
2025-06-27	2025 Annual Meeting – Replay Instructions	Shareholder meeting
2023-11-05	38th Annual SITC Conference	Conference
2023-04-19	HCW9218 Underlying Mechanism of Action Against Solid Tumors, AACR Annual Meeting 2023	Shareholder meeting
2022-11-14	A Phase 1 Study of HCW9218, a Bifunctional TGF-β Antagonist/IL-15 Protein Complex, in Advanced Solid Tumors, SITC Annual Meeting 2022	Shareholder meeting
2022-05-09	Robust human regulatory T cell expansion with fusion proteins HCW9302 and HCW9213 circumvents need for magnetic-bead or feeder cell approaches for adoptive cell therapy – Immunology 2022	Event
2022-05-09	A “kick and expand” strategy to generate large numbers of CIML NK cells for adoptive cell therapy for the treatment of cancer using novel fusion proteins HCW9201 and HCW9206 – Immunology 2022	Event